The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | How can MRD and disease be assessed in routine practice?
Joan Bladé
• 21 Apr 2017
Joan Bladé, MD, from Hospital Clinic, Barcelona, Spain, discusses criteria for myeloma disease assessment and how these have changed at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He speaks about different criteria which can be assessed, and discusses how often patients should be monitored during and after treatment to determine the depth of response.
